October 2012 – Principal Investigator: GMA-LAS-12-023: A Multi-Center, Double-Masked, Randomized, Active-And-Placebo-Controlled Evaluation of the Efficacy of Action of Lastacaft (Alcaftadine 0.25%) Ophthalmic Solution Compared to Pataday and Placebo in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
June 2012 – Prinicipal Investigator: OMS302-ILR-004: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Pharmocokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement with Phacoemulsification
October 2011 – Principal Investigator: OMS302-ILR-003: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
July 2011 – Principal Investigator: B & L 661: A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens Design
June 2011 – Principal Investigator: B & L 637: A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
April 2011 – Principal Investigator: A Study to Evaluate the Safety and Efficacy of a Novel Contact Lens Used in Healthy, Normal Volunteers that Live in an Urban Environment.
November 2010 – Principal Investigator: B & L Study 685 / 10-100-0021: A Multi-Center, Randomized, Evaluation of the Efficacy of BOL-303242-X (Maprocorat) Ophthalmic Suspension, (0.3%, 2%, and 3%) Compared to Vehicle in a Modified Conjunctival Allergen Challenge (CAC)
November 2010 – Principal Investigator: OMS302 C09-001: “A Study of Phenylephrine HCl’s and Ketorolac Tromethamine’s Ability, Alone and in Combination, to Maintain Mydriasis and Relieve Pain and Inflammation in Subjects Undergoing Unilateral Cataract Extraction with Lens Replacement (CELR)”
September 2010 – Principal Investigator: FOV1101/CLIN/202//P: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation
May 2010 – Principal Investigator: Aciex Therapeutics 10-100-0005: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1% / Fluticasone 0.005% Ophthalmic Solution Compared to its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
April 2010 – Principal Investigator: B & L 572 / 07-003-21: A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of Ketonaph (Ketotifen Fumarate 0.025%, Naphazoline HC1 0.05%) Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
March 2009 – Principal Investigator: A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Co-Administration of FOV1101-00 (Cyclosporine 0.01% or 0.02%) and Prednisolone Acetate 0.12% (Pred Mild®) Compared to its Components and Vehicle in Patients with Mild Ongoing Ocular Allergic Inflammation.
June 2008 – Principal Investigator: A Study to Evaluate the Clinical Performance of a Novel Multi-Purpose Solution.
January 2008 – Sub Investigator: Multi Center, Double Masked, Placebo Controlled, Evaluation of the Onset and Duration of Action of Two Concentrations of Bepotastine Besilate Ophthalmic Solution in the Conjunctival Allergen Challenge
November 2007 – Sub Investigator: Multi – Center, randomized, Double Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers.
August 2007 – Sub Investigator: The efficacy, safety and tolerability of travoprost bak free 0.0004% (Travatan Z) compared to prior treatment with Latanoprost 0.0005%) in patients of Japanese origin.
May 2006 – Sub Investigator: Multi-Centered Evaluation of the Efficacy and Clinical Performance of the Duration of Action of Patanol Ophthalmic Solution vs. Livostin Ophthalmic Suspension Using the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis in Japanese Subjects.
February 2006 – Principal Investigator: A study to evaluate the clnical and microbial eficacy of 0.6% ISV-403 compared to Vigamox in the treatment of bacterial conjunctivitis.
